CN105287478A - Medicine composition for treating gastritis - Google Patents
Medicine composition for treating gastritis Download PDFInfo
- Publication number
- CN105287478A CN105287478A CN201510755108.6A CN201510755108A CN105287478A CN 105287478 A CN105287478 A CN 105287478A CN 201510755108 A CN201510755108 A CN 201510755108A CN 105287478 A CN105287478 A CN 105287478A
- Authority
- CN
- China
- Prior art keywords
- compound
- gastritis
- pharmaceutical composition
- treatment
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a medicine composition for treating gastritis. The medicine composition comprises an effective quantity of compounds and a pharmaceutically-acceptable carrier, and the structure of the compounds is shown in the specification. The composition has the remarkable effect on pathogenic bacteria causing gastritis, and can be developed into a new clinically-effective medicine composition.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to a kind of pharmaceutical composition for the treatment of gastritis.
Background technology
Gastritis is digestion section office commonly encountered diseases, also be current common clinical, gastritis majority is caused by helicobacter pylori, but recent discovery performance, other pathogenic bacterias also may cause stomach environment change, find that in the recent period eubacterium lentum ATCC43055 is also one of pathogenic bacteria wherein.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of gastritis.
In order to realize object of the present invention, the invention provides a kind of compound for the treatment of gastritis, this compound has having structure:
The present invention also provides a kind of pharmaceutical composition for the treatment of gastritis, and described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
Preferably, described pharmaceutically acceptable carrier is diluent, disintegrating agent, binding agent, lubricant, stabilizing agent or corrigent.
Preferably, described diluent is sugar derivatives, starch derivatives or cellulose derivative.
Preferably, described diluent is lactose.
Preferably, described pharmaceutical composition is powder, microgranule, granule, capsule or tablet.
The present invention also provides the purposes of compound in the medicine of preparation treatment gastritis, and this compound has having structure:
Preferably, described infection is caused by eubacterium lentum ATCC43055.
The present invention also provides the purposes of compound in the medicine of preparation vitro inhibition eubacterium lentum ATCC43055, and this compound has having structure:
Term used herein " pharmaceutically acceptable " refers to not eliminate the biologic activity of compound as herein described or the material of character, as carrier or diluent.This kind of material is applied to and individual does not cause undesirable biological action or not with harmful way and any component interaction comprised in its compositions.
" pharmaceutically acceptable carrier " comprises any and all solvents as the term is employed herein, disperse medium, coating material, surfactant, antioxidant, antiseptic (such as antibacterial, antifungal), isotonic agent, absorption delay agent, salt, antiseptic, drug stabilizing agent, binding agent, excipient, disintegrating agent, lubricant, sweeting agent, correctives, dyestuff etc. and its combination, this is well-known to those skilled in the art (for example, see Remington'sPharmaceuticalSciences, 18thEd.MackPrintingCompany, 1990, pp.1289-1329).Except with except the inconsistent carrier of active component, consider to use any conventional carrier in treatment or pharmaceutical composition.
Compound of the present invention, for the pathogen Be very effective causing gastrointestinal, can be developed to pharmaceutical composition effectively new clinically.
Detailed description of the invention
Below by way of the description of detailed description of the invention, the invention will be further described, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, various amendment or improvement can be made, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
The research of the purposes of experimental example the compounds of this invention in the medicine of preparation vitro inhibition eubacterium lentum ATCC43055
Bacteriostatic test
Use following compounds, adopt filter paper enzyme classical in this area to carry out bacteriostatic test, wherein:
The structural formula of target compound is:
For examination strain eubacterium lentum ATCC43055 purchased from Bei Nuo bio tech ltd, Shanghai.
Culture fluid
Nutrient agar and nutrient broth, purchased from Chen Yu experimental facilities company limited of BeiJing ZhongKe.
Test method
Eubacterium lentum ATCC43055 is inoculated in agar plate nutritional solution plane, evenly gathers during inoculation.
Take target compound 0.01 gram, add 15000 ml sterile waters, ultrasonic 30 minutes, then the filtering with microporous membrane of 0.22 μm, obtained solution.The aseptic circular filter paper sheet of tweezer, sprays above-mentioned solution to complete wetting, is attached in the agar plate nutritional solution plane of inoculated bacteria.Agar plate is placed in the incubator of 37 DEG C, incubation 4 hours.Measure the diameter of bacterial restrain.Measure and average for 3 times.
1.4 result
The average diameter of the bacterial restrain of eubacterium lentum ATCC43055 is 13.86mm, and this shows that target compound has the effect of extremely strong vitro inhibition eubacterium lentum ATCC43055.
Claims (9)
1. treat a compound for gastritis, it is characterized in that, this compound has having structure:
2. treat a pharmaceutical composition for gastritis, it is characterized in that, described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
3. the pharmaceutical composition for the treatment of gastritis according to claim 2, is characterized in that, described pharmaceutically acceptable carrier is diluent, disintegrating agent, binding agent, lubricant, stabilizing agent or corrigent.
4. the pharmaceutical composition for the treatment of gastritis according to claim 3, is characterized in that, described diluent is sugar derivatives, starch derivatives or cellulose derivative.
5. the pharmaceutical composition for the treatment of gastritis according to claim 4, is characterized in that, described diluent is lactose.
6. the pharmaceutical composition for the treatment of gastritis according to claim 3, is characterized in that, described pharmaceutical composition is powder, microgranule, granule, capsule or tablet.
7. the purposes of compound in the medicine of preparation treatment gastritis, it is characterized in that, this compound has having structure:
8. purposes according to claim 7, is characterized in that, described infection is caused by eubacterium lentum ATCC43055.
9. the purposes of compound in the medicine of preparation vitro inhibition eubacterium lentum ATCC43055, it is characterized in that, this compound has having structure:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510755108.6A CN105287478B (en) | 2015-11-09 | 2015-11-09 | A kind of pharmaceutical composition treating gastritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510755108.6A CN105287478B (en) | 2015-11-09 | 2015-11-09 | A kind of pharmaceutical composition treating gastritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105287478A true CN105287478A (en) | 2016-02-03 |
| CN105287478B CN105287478B (en) | 2016-09-21 |
Family
ID=55185772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510755108.6A Expired - Fee Related CN105287478B (en) | 2015-11-09 | 2015-11-09 | A kind of pharmaceutical composition treating gastritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105287478B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3947594A (en) * | 1973-05-07 | 1976-03-30 | Gaf Corporation | 4-Halo-1-hydroxyanthraquinone containing fungicidal composition |
| CN1345716A (en) * | 2000-09-26 | 2002-04-24 | 上海市中药研究所 | Process for extracting and separating anthraquinone compound from Chinese herbal medicinal material |
-
2015
- 2015-11-09 CN CN201510755108.6A patent/CN105287478B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3947594A (en) * | 1973-05-07 | 1976-03-30 | Gaf Corporation | 4-Halo-1-hydroxyanthraquinone containing fungicidal composition |
| CN1345716A (en) * | 2000-09-26 | 2002-04-24 | 上海市中药研究所 | Process for extracting and separating anthraquinone compound from Chinese herbal medicinal material |
Non-Patent Citations (2)
| Title |
|---|
| 刘德胜等: "胃肠舒片中总蒽醌及5种游离蒽醌的含量测定", 《中药材》 * |
| 胡观明: "蒽醌类化合物的合成及对肿瘤细胞的细胞毒活性的研究", 《中国优秀硕士学位论文全文数据库》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105287478B (en) | 2016-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104083364B (en) | A kind of pharmaceutical composition for the treatment of the infantile respiratory tract infection that enterobacter cloacae causes | |
| CN105198903B (en) | A kind of pharmaceutical composition treating acute upper respiratory tract infection | |
| CN105412076B (en) | Compound purposes in the medicine of preparation treatment infantile diarrhea | |
| CN104086541B (en) | A kind of pharmaceutical composition for the treatment of infantile respiratory tract infection | |
| CN105232542B (en) | A kind of pharmaceutical composition for the treatment of infantile pneumonia | |
| CN105232540A (en) | Drug combination for treating infection after burn | |
| CN105287478A (en) | Medicine composition for treating gastritis | |
| CN105085503A (en) | Medicine composition for treating respiratory tract infection | |
| CN105348183A (en) | Pharmaceutical composition for treating gynecology-and-obstetrics postoperative low-fever symptom | |
| CN105294535A (en) | Pharmaceutical composition used for treating pelvic inflammation | |
| CN105748477B (en) | A kind of medicine treating infantile enteritiss | |
| CN105237542A (en) | Medicine composition for treating gynecological diseases | |
| CN105061331A (en) | Pharmaceutical composition for eliminating phlegm for children | |
| CN105622619A (en) | Medicine composition for treating periodontitis | |
| CN105232550B (en) | A kind of pharmaceutical composition treating chronic pelvic inflammatory disease | |
| CN105232504A (en) | Medicine composition for treating infant recurrent respiratory tract infections | |
| CN105748478B (en) | A kind of medicine treating infantile diarrhea | |
| CN105218460A (en) | A kind of pharmaceutical composition for the treatment of enteritis | |
| CN105254477A (en) | Medicine composition for treatment of vaginitis | |
| CN105395538A (en) | Medicine composition treating acute upper respiratory infection | |
| CN105125546A (en) | Medicine composition for treating postoperative wound infection | |
| CN105560234A (en) | Medicine composition for treating oral and maxillofacial inflammation | |
| CN105687189A (en) | Medicine composition for treating upper respiratory tract infection | |
| CN105254700A (en) | Medicinal composition for treatment of infection after scald | |
| CN105777612A (en) | Medicine composition for treating children recurrent respiratory infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Xu Li Inventor after: Sun Xiangrong Inventor after: Guo Feifei Inventor after: Xu Ran Inventor after: Zhang Yanzhi Inventor before: Wei Fang |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160818 Address after: 266000 No. 308, Ningxia Road, Laoshan District, Shandong, Qingdao Applicant after: Qingdao University Address before: 071003 Hebei Province, Baoding City area Yonghua No. 19 North Street Applicant before: Wei Fang |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160921 Termination date: 20191109 |